Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $101.31 USD
Change Today +0.91 / 0.91%
Volume 1.1M
As of 8:04 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-sponsored adr (NVS) Snapshot

Open
$100.38
Previous Close
$100.40
Day High
$101.56
Day Low
$100.34
52 Week High
02/9/15 - $103.50
52 Week Low
04/7/14 - $82.27
Market Cap
274.2B
Average Volume 10 Days
1.4M
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
03/2/15
P/E TM
--
Dividend
$2.82
Dividend Yield
2.78%
Current Stock Chart for NOVARTIS AG-SPONSORED ADR (NVS)

novartis ag-sponsored adr (NVS) Related Businessweek News

View More BusinessWeek News

novartis ag-sponsored adr (NVS) Details

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company’s Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

133,413 Employees
Last Reported Date: 01/27/15
Founded in 1895

novartis ag-sponsored adr (NVS) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.6.1M
Chief Financial Officer
Total Annual Compensation: SFr.2.6M
President of Institutes for Biomedical Resear...
Total Annual Compensation: $3.0M
Global Head of Novartis Business Services and...
Total Annual Compensation: SFr.1.2M
Division Head of Novartis Pharmaceuticals
Total Annual Compensation: $3.9M
Compensation as of Fiscal Year 2014.

novartis ag-sponsored adr (NVS) Key Developments

Novartis Accelerates Cancer Immunotherapy Efforts with Aduro Biotech Alliance and Launch of New Immuno-Oncology Research Group

Novartis announced that it is stepping up its efforts to harness the body's immune system to combat cancer. The company has entered into a major multiyear alliance with Aduro Biotech that is focused on the discovery and development of next generation cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway and launched a new immuno-oncology research group led by renowned cancer vaccine expert Glenn Dranoff, MD. The addition of STING agonists adds firepower to Novartis' diverse portfolio of immunotherapies that includes chimeric antigen receptor T-cell (CART) technology and novel checkpoint inhibitors. Currently the CART program, CTL019, is in phase 2 clinical trials and checkpoint inhibitors targeting PD1, LAG3, and TIM3 are expected to enter the clinic in mid-2015. Under the terms of the agreement with Aduro, Novartis will make an upfront payment of $200 million to Aduro and will make an initial equity investment in the company for $25 million, with a commitment for another $25 million equity investment at a future date. Aduro will lead commercialization activities and book sales in the US, with Novartis leading commercialization and recognizing sales in the rest of the world. The companies will share in profits in the US, Japan and major European countries. Novartis will pay Aduro a royalty for sales in the rest of the world.

Novartis Announces Encouraging Two-Year Data from Psoriasis Study

Novartis has announced new two-year data from the extension study of the pivotal Phase III FIXTURE and ERASURE trials demonstrating sustained efficacy with Cosentyx with an acceptable safety profile for the treatment of psoriasis patients. Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved to treat adult moderate-to-severe plaque psoriasis patients. In this extension of the FIXTURE and ERASURE studies, 995 patients who achieved Psoriasis Area Severity Index (PASI) 75 response after a year of therapy (Week 52) received either Cosentyx 300 mg, Cosentyx 150 mg or placebo for an additional year (Week 104). After two full years of therapy, 7 out of 10 (70.6%) patients treated with Cosentyx 300 mg had clear to almost clear skin (PASI 90); 4 out of 10 (43.9%) had clear skin (PASI 100) and almost 9 out of 10 (88.2%) patients maintained their PASI 75 response at Week 104. For patients treated with Cosentyx 150 mg, 44.6% had clear or almost clear skin (PASI 90); 23.5% had clear skin (PASI 100) and 75.5% maintained their PASI 75 response at Week 104. PASI assesses treatment efficacy by measuring the reduction in redness, scaling and thickness of psoriatic plaques and the extent of involvement in each region of the body.

Sandoz Ltd. Wins GBP 220.9 Million Multiple Awardees Contract for Supplying Proprietary Pharmaceuticals

Sandoz Ltd. won a GBP 220.9 million (excluding VAT) multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of proprietary pharmaceuticals (Contract Award Notice No.: 2015/S 057-099494).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $101.31 USD +0.91

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $100.69 USD -0.31
Johnson & Johnson $101.55 USD +1.21
Merck & Co Inc $58.34 USD +0.59
Pfizer Inc $35.00 USD +0.47
Roche Holding AG SFr.269.00 CHF +4.00
View Industry Companies
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 23.2x
Price/Sales 4.5x
Price/Book 3.4x
Price/Cash Flow 26.5x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.